CD28-specific immunomodulating antibodies: What can be learned from experimental models?

American Journal of Transplantation

Volumn 12, Issue 7, 2012, Pages 1682-1690

  Poirier, N ^a,b,c   Blancho, G ^a,b   Vanhove, Bernard ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c Effimune SAS   (France)

Author keywords

Alloreactivity; Autoimmunity; Immune tolerance; Immunomodulation; Kidney transplantation; Regulatory T cells

Indexed keywords

ANTIBODY; B7 ANTIGEN; CD28 ANTIBODY; CD28 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; FC RECEPTOR; UNCLASSIFIED DRUG;

ALLOIMMUNITY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOPATHOLOGY; IMMUNOREGULATION; KIDNEY TRANSPLANTATION; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SHORT SURVEY; T LYMPHOCYTE; TRANSPLANTATION;

EID: 84863205297     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2012.04032.x     Document Type: Short Survey

References (76)

1. Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 2007; 27: 111-122. (Pubitemid 47089023)
2. Butte MJ, Pena-Cruz V, Kim MJ, Freeman GJ, Sharpe AH. Interaction of human PD-L1 and B7-1. Mol Immunol 2008; 45: 3567-3572.
3. Yao S, Zhu Y, Zhu G, et al. B7-h2 is a costimulatory ligand for CD28 in human. Immunity 2011; 34: 729-740.
4. Poirier N, Blancho G, Vanhove B. A more selective costimulatory blockade of the CD28-B7 pathway. Transpl Int 2011; 24: 2-11.
5. Tacke M, Hanke G, Hanke T, Hunig T. CD28-mediated induction of proliferation in resting T cells in vitro and in vivo without engagement of the T cell receptor: Evidence for functionally distinct forms of CD28. Eur J Immunol 1997; 27: 239-247. (Pubitemid 27046084)
6. Luhder F, Huang Y, Dennehy KM, et al. Topological requirements and signaling properties of T cell-activating, anti-CD28 antibody superagonists. J Exp Med 2003; 197: 955-966. (Pubitemid 36523193)
7. Lin CH, Hunig T. Efficient expansion of regulatory T cells in vitro and in vivo with a CD28 superagonist. Eur J Immunol 2003; 33: 626-638. (Pubitemid 36367666)
8. Hunig T. Manipulation of regulatory T-cell number and function with CD28-specific monoclonal antibodies. Adv Immunol 2007; 95: 111-148. (Pubitemid 47380504)
9. Azuma H, Isaka Y, Li X, et al. Superagonistic CD28 antibody induces donor-specific tolerance in rat renal allografts. Am J Transplant 2008; 8: 2004-2014.
10. Kitazawa Y, Fujino M, Sakai T, et al. Foxp3-expressing regulatory T cells expanded with CD28 superagonist antibody can prevent rat cardiac allograft rejection. J Heart Lung Transplant 2008; 27: 362-371. (Pubitemid 351418241)
11. Legrand N, Cupedo T, van Lent AU, et al. Transient accumulation of human mature thymocytes and regulatory T cells with CD28 superagonist in "human immune system" Rag2(-/-)gammac(-/-) mice. Blood 2006; 108: 238-245. (Pubitemid 43990634)
12. Muller N, van den Brandt J, Odoardi F, et al. A CD28 superagonistic antibody elicits 2 functionally distinct waves of T cell activation in rats. J Clin Invest 2008; 118: 1405-1416. (Pubitemid 351500434)
13. Gogishvili T, Langenhorst D, Luhder F, et al. Rapid regulatory T-cell response prevents cytokine storm in CD28 superagonist treated mice. PLoS One 2009; 4: e4643.
14. Schmidt J, Elflein K, Stienekemeier M, et al. Treatment and prevention of experimental autoimmune neuritis with superagonistic CD28-specific monoclonal antibodies. J Neuroimmunol 2003; 140: 143-152. (Pubitemid 36836099)
15. Beyersdorf N, Gaupp S, Balbach K, et al. Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis. J Exp Med 2005; 202: 445-455. (Pubitemid 41126962)
16. Tischner D, Weishaupt A, van den Brandt J, et al. Polyclonal expansion of regulatory T cells interferes with effector cell migration in a model of multiple sclerosis. Brain 2006; 129(Pt 10): 2635-2647. (Pubitemid 44522097)
17. Beaudette-Zlatanova BC, Whalen B, Zipris D, et al. Costimulation and autoimmune diabetes in BB rats. Am J Transplant 2006; 6(5 Pt 1): 894-902. (Pubitemid 44356639)
18. Takabatake Y, Li XK, Mizui M, et al. A superagonistic monoclonal antibody for CD28 ameliorates crescentic glomerulonephritis in wistar-kyoto rats. Mol Med 2011; 17: 686-696.
19. Wang S, Liu J, Wang M, Zhang J, Wang Z. Treatment and prevention of experimental autoimmune myocarditis with CD28 superagonists. Cardiology 2010; 115: 107-113.
20. Rodriguez-Palmero M, Franch A, Castell M, et al. Effective treatment of adjuvant arthritis with a stimulatory CD28-specific monoclonal antibody. J Rheumatol 2006; 33: 110-118. (Pubitemid 43054290)
21. Beyersdorf N, Ding X, Hunig T, Kerkau T. Superagonistic CD28 stimulation of allogeneic T cells protects from acute graft-versus-host disease. Blood 2009; 114: 4575-4582.
22. Urakami H, Ostanin DV, Hunig T, Grisham MB. Combination of donor-specific blood transfusion with anti-CD28 antibody synergizes to prolong graft survival in rat liver transplantation. Transplant Proc 2006; 38: 3244-3246. (Pubitemid 44908429)
23. TeGenero Immunotherapeutics Investigator's brochure. TGN1412 - humanized agonistic anti-CD28 monoclonal antibody, edn 1.1 2005-12-19. Würzburg: TeGenero AG, 2005. Available at: http://www.circare.org/foia5/ tgn1412investigatorbrochure.pdf. Accessed Oct 18, 2006.
24. Ohresser M, Olive D, Vanhove B, Watier H. Risk in drug trials. Lancet 2006; 368: 2205-2206. (Pubitemid 46039755)
25. Schraven B, Kalinke U. CD28 superagonists: What makes the difference in humans? Immunity 2008; 28: 591-595. (Pubitemid 351636245)
26. Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006; 355: 1018-1028. (Pubitemid 44343545)
27. Waibler Z, Sender LY, Merten C, et al. Signaling signatures and functional properties of anti-human CD28 superagonistic antibodies. PLoS One 2008; 3: e1708.
28. Eastwood D, Findlay L, Poole S, et al. Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells. Br J Pharmacol 2010; 161: 512-526.
29. Soto PC, Stein LL, Hurtado-Ziola N, Hedrick SM, Varki A. Relative over-reactivity of human versus chimpanzee lymphocytes: implications for the human diseases associated with immune activation. J Immunol 2010; 184: 4185-4195.
30. Nguyen DH, Hurtado-Ziola N, Gagneux P, Varki A. Loss of Siglec expression on T lymphocytes during human evolution. Proc Natl Acad Sci U S A 2006; 103: 7765-7770.
31. Vanhove B, Laflamme G, Coulon F, et al. Selective blockade of CD28 and not CTLA-4 with a single-chain Fv-alpha1-antitrypsin fusion antibody. Blood 2003; 102: 564-570. (Pubitemid 36841976)
32. Shiao SL, McNiff JM, Masunaga T, Tamura K, Kubo K, Pober JS. Immunomodulatory properties of FK734, a humanized anti-CD28 monoclonal antibody with agonistic and antagonistic activities. Transplantation 2007; 83: 304-313.
33. Silver PB, Hathcock KS, Chan CC, Wiggert B, Caspi RR. Blockade of costimulation through B7/CD28 inhibits experimental autoimmune uveoretinitis, but does not induce long-term tolerance. J Immunol 2000; 165: 5041-5047.
34. Arreaza GA, Cameron MJ, Jaramillo A, et al. Neonatal activation of CD28 signaling overcomes T cell anergy and prevents autoimmune diabetes by an IL-4-dependent mechanism. J Clin Invest 1997; 100: 2243-2253. (Pubitemid 27500147)
35. Yu XZ, Bidwell SJ, Martin PJ, Anasetti C. CD28-specific antibody prevents graft-versus-host disease in mice. J Immunol 2000; 164: 4564-4568. (Pubitemid 30238053)
36. Yu XZ, Albert MH, Martin PJ, Anasetti C. CD28 ligation induces transplantation tolerance by IFN-gamma-dependent depletion of T cells that recognize alloantigens. J Clin Invest 2004; 113: 1624-1630. (Pubitemid 39071686)
37. Beyersdorf N, Ding X, Blank G, Dennehy KM, Kerkau T, Hunig T. Protection from graft-versus-host disease with a novel B7 binding site-specificmouse anti-mouse CD28monoclonal antibody. Blood 2008; 112: 4328-4336.
38. Mirenda V, Jarmin SJ, David R, et al. Physiologic and aberrant regulation of memory T-cell trafficking by the costimulatory molecule CD28. Blood 2007; 109: 2968-2977. (Pubitemid 46482095)
39. Dengler TJ, Szabo G, Sido B, et al. Prolonged allograft survival but no tolerance induction by modulating CD28 antibody JJ319 after high-responder rat heart transplantation. Transplantation 1999; 67: 392-398. (Pubitemid 29094009)
40. Dong VM, Yuan X, Coito AJ, Waaga AM, Sayegh MH, Chandraker A. Mechanisms of targeting CD28 by a signaling monoclonal antibody in acute and chronic allograft rejection. Transplantation 2002; 73: 1310-1317. (Pubitemid 34454281)
41. Haspot F, Villemain F, Laflamme G, et al. Differential effect of CD28 versus B7 blockade on direct pathway of allorecognition and self-restricted responses. Blood 2002; 99: 2228-2234. (Pubitemid 34525511)
42. Laskowski IA, Pratschke J, Wilhelm MJ, et al. Anti-CD28 monoclonal antibody therapy prevents chronic rejection of renal allografts in rats. J Am Soc Nephrol 2002; 13: 519-527. (Pubitemid 34106296)
43. Haspot F, Seveno C, Dugast AS, et al. Anti-CD28 antibody-induced kidney allograft tolerance related to tryptophan degradation and TCR class II B7 regulatory cells. Am J Transplant 2005; 5: 2339-2348.
44. Guillonneau C, Seveno C, Dugast AS, et al. Anti-CD28 antibodies modify regulatory mechanisms and reinforce tolerance in CD40Ig-treated heart allograft recipients. J Immunol 2007; 179: 8164-8171.
45. Dugast AS, Haudebourg T, Coulon F, et al. Myeloid-derived suppressor cells accumulate in kidney allograft tolerance and specifically suppress effector T cell expansion. J Immunol 2008; 180: 7898-7906.
46. Jang MS, Pan F, Erickson LM, et al. A blocking anti-CD28-specific antibody induces long-term heart allograft survival by suppression of the PKC theta-JNK signal pathway. Transplantation 2008; 85: 1051-1055. (Pubitemid 351543171)
47. Raychaudhuri SP, Kundu-Raychaudhuri S, Tamura K, et al. FR255734, a humanized, Fc-Silent, Anti-CD28 antibody, improves psoriasis in the SCID mouse-psoriasis xenograft model. J Invest Dermatol 2008; 128: 1969-1976. (Pubitemid 352001220)
48. Tan P, Anasetti C, Hansen JA, et al. Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. J Exp Med 1993; 177: 165-173. (Pubitemid 23008096)
49. Poirier N, Azimzadeh AM, Zhang T, et al. Inducing CTLA-4-dependent immune regulation by selective CD28 blockade promotes regulatory T cells in organ transplantation. Sci Transl Med 2010; 2: 17ra10.
50. Schneider H, Downey J, Smith A, et al. Reversal of the TCR stop signal by CTLA-4. Science 2006; 313: 1972-1975. (Pubitemid 44498006)
51. Hugues S, Fetler L, Bonifaz L, Helft J, Amblard F, Amigorena S. Distinct T cell dynamics in lymph nodes during the induction of tolerance and immunity. Nat Immunol 2004; 5: 1235-1242. (Pubitemid 41057738)
52. Sakaguchi S, Sakaguchi N, Shimizu J, et al. Immunologic tolerance maintained by CD25+CD4+regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001; 182: 18-32. (Pubitemid 33070205)
53. Perrin PJ, June CH, Maldonado JH, Ratts RB, Racke MK. Blockade of CD28 during in vitro activation of encephalitogenic T cells or after disease onset ameliorates experimental autoimmune encephalomyelitis. J Immunol 1999; 163: 1704-1710. (Pubitemid 29352797)
54. Zhang T, Fresnay S, Welty E, et al. Selective CD28 blockade attenuates acute and chronic rejection of murine cardiac allografts in a CTLA-4-dependent manner. Am J Transplant 2011; 11: 1599-1609.
55. Alvarez-Quiroga C, Abud-Mendoza C, Doniz-Padilla L, et al. CTLA-4-Ig therapy diminishes the frequency but enhances the function of Treg cells in patients with rheumatoid arthritis. J Clin Immunol 2011; 31: 588-595.
56. Bluestone JA, Liu W, Yabu JM, et al. The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am J Transplant 2008; 8: 2086-2096.
57. Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10: 535-546.
58. Riella LV, Liu T, Yang J, et al. Deleterious effect of CTLA4-Ig on a Treg-Dependent Transplant Model. Am J Transplant 2012; 12: 846-855.
59. Tang Q, Henriksen KJ, Boden EK, et al. Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. J Immunol 2003; 171: 3348-3352. (Pubitemid 37254533)
60. Salomon B, Lenschow DJ, Rhee L, et al. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 2000; 12: 431-440.
61. Ito T, Hanabuchi S, Wang YH, et al. Two functional subsets of FOXP3+ regulatory T cells in human thymus and periphery. Immunity 2008; 28: 870-880.
62. Chen Y, Shen S, Gorentla BK, Gao J, Zhong XP. Murine regulatory T cells contain hyperproliferative and death-prone subsets with differential ICOS expression. J Immunol 2012; 188: 1698-1707.
63. Benson MJ, Pino-Lagos K, Rosemblatt M, Noelle RJ. All-trans retinoic acid mediates enhanced T reg cell growth, differentiation, and gut homing in the face of high levels of co-stimulation. J Exp Med 2007; 204: 1765-1774. (Pubitemid 47236315)
64. Semple K, Nguyen A, Yu Y, Wang H, Anasetti C, Yu XZ. Strong CD28 costimulation suppresses induction of regulatory T cells from naive precursors through LCK signaling. Blood 2011; 117: 3096-3103.
65. Fu S, Zhang N, Yopp AC, et al. TGF-beta induces Foxp3 +T-regulatory cells from CD4 + CD25 - precursors. Am J Transplant 2004; 4: 1614-1627. (Pubitemid 39312295)
66. Zheng SG, Wang JH, Stohl W, Kim KS, Gray JD, Horwitz DA. TGF-beta requires CTLA-4 early after T cell activation to induce FoxP3 and generate adaptive CD4+CD25 +regulatory cells. J Immunol 2006; 176: 3321-3329. (Pubitemid 43363978)
67. Vasu C, Prabhakar BS, Holterman MJ. Targeted CTLA-4 engagement induces CD4+CD25+CTLA-4high T regulatory cells with target (allo)antigen specificity. J Immunol 2004; 173: 2866-2876. (Pubitemid 39063149)
68. Li R, Perez N, Karumuthil-Melethil S, Prabhakar BS, Holterman MJ, Vasu C. Enhanced engagement of CTLA-4 induces antigen-specific CD4+CD25+Foxp3+ and CD4+CD25- TGF-beta 1+ adaptive regulatory T cells. J Immunol 2007; 179: 5191-5203.
69. Mellor AL, Munn DH. IDO expression by dendritic cells: Tolerance and tryptophan catabolism. Nat Rev Immunol 2004; 4: 762-774. (Pubitemid 39336293)
70. Sharma MD, Baban B, Chandler P, et al. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest 2007; 117: 2570-2582. (Pubitemid 47494358)
71. Chen W, Liang X, Peterson AJ, Munn DH, Blazar BR. The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation. J Immunol 2008; 181: 5396-5404.
72. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol 2005; 23: 515-548. (Pubitemid 40563179)
73. Wing K, Onishi Y, Prieto-Martin P, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 2008; 322: 271-275.
74. Takahashi T, Tagami T, Yamazaki S, et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 2000; 192: 303-310.
75. Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003; 349: 1907-1915. (Pubitemid 37409707)
76. Vincenti F, Larsen CP, Alberu J, et al. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant 2012; 12: 210-217.